JP2018533371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533371A5 JP2018533371A5 JP2018536698A JP2018536698A JP2018533371A5 JP 2018533371 A5 JP2018533371 A5 JP 2018533371A5 JP 2018536698 A JP2018536698 A JP 2018536698A JP 2018536698 A JP2018536698 A JP 2018536698A JP 2018533371 A5 JP2018533371 A5 JP 2018533371A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- abp
- sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 239
- 108091000831 antigen binding proteins Proteins 0.000 claims description 239
- 239000003814 drug Substances 0.000 claims description 71
- 102000039446 nucleic acids Human genes 0.000 claims description 65
- 108020004707 nucleic acids Proteins 0.000 claims description 65
- 150000007523 nucleic acids Chemical class 0.000 claims description 65
- 239000003795 chemical substances by application Substances 0.000 claims description 59
- 229940124597 therapeutic agent Drugs 0.000 claims description 53
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 33
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 32
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 32
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 32
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 230000003993 interaction Effects 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 210000002865 immune cell Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 20
- 239000000556 agonist Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 20
- 244000309459 oncolytic virus Species 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- -1 MAB6 Proteins 0.000 claims description 17
- 108091008042 inhibitory receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 230000004936 stimulating effect Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102000049823 human TIGIT Human genes 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 11
- 102100024263 CD160 antigen Human genes 0.000 claims description 10
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 10
- 238000012575 bio-layer interferometry Methods 0.000 claims description 10
- 230000003308 immunostimulating effect Effects 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 8
- 102100029740 Poliovirus receptor Human genes 0.000 claims description 8
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 6
- 102100035488 Nectin-2 Human genes 0.000 claims description 6
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 101150013553 CD40 gene Proteins 0.000 claims description 5
- 102100035793 CD83 antigen Human genes 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 5
- 101150046249 Havcr2 gene Proteins 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 5
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 5
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 5
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 5
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 5
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 5
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 5
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 5
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 5
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 108010002616 Interleukin-5 Proteins 0.000 claims description 5
- 108010002586 Interleukin-7 Proteins 0.000 claims description 5
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 101150030213 Lag3 gene Proteins 0.000 claims description 5
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 5
- 241001372913 Maraba virus Species 0.000 claims description 5
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 5
- 102100028749 Neuritin Human genes 0.000 claims description 5
- 101710189685 Neuritin Proteins 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 5
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- WMPXPUYPYQKQCX-UHFFFAOYSA-N Sulfamonomethoxine Chemical compound C1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 WMPXPUYPYQKQCX-UHFFFAOYSA-N 0.000 claims description 5
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 5
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 5
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229960003852 atezolizumab Drugs 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 229950009791 durvalumab Drugs 0.000 claims description 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 229960003301 nivolumab Drugs 0.000 claims description 5
- 229960002621 pembrolizumab Drugs 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 229950003874 sulfamonomethoxine Drugs 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- YJSXHUXXMDAOCE-UHFFFAOYSA-N 5-hydroxy-8,8-dimethyl-6-(2-methylbutanoyl)-4-phenylpyrano[2,3-h]chromen-2-one Chemical compound C=1C(=O)OC=2C=3C=CC(C)(C)OC=3C(C(=O)C(C)CC)=C(O)C=2C=1C1=CC=CC=C1 YJSXHUXXMDAOCE-UHFFFAOYSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 4
- AVIZABGQXBMRCJ-UHFFFAOYSA-N Mammea A/AB cyclo F Chemical compound C12=C(O)C(C(=O)C(C)CC)=C3OC(C(C)(C)O)CC3=C2OC(=O)C=C1C1=CC=CC=C1 AVIZABGQXBMRCJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 claims description 4
- 229960005158 sulfamethizole Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- AVIZABGQXBMRCJ-DYVFJYSZSA-N 1,2-Dihydro-5-hydroxy-2-(1-hydroxy-1-methylethyl)-4-(2-methylbutyryl)-6-phenylfurano[2,3-h][1]benzopyran-8-one Natural products O=C([C@@H](CC)C)c1c(O)c2C(c3ccccc3)=CC(=O)Oc2c2c1O[C@H](C(O)(C)C)C2 AVIZABGQXBMRCJ-DYVFJYSZSA-N 0.000 claims description 2
- 101100344898 Arabidopsis thaliana MED13 gene Proteins 0.000 claims description 2
- 101100516975 Arabidopsis thaliana NPY1 gene Proteins 0.000 claims description 2
- 101100350216 Arabidopsis thaliana PDH2 gene Proteins 0.000 claims description 2
- 101100022187 Caenorhabditis elegans mab-10 gene Proteins 0.000 claims description 2
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 claims description 2
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 claims description 2
- 101100075831 Caenorhabditis elegans mab-7 gene Proteins 0.000 claims description 2
- 101100313161 Caenorhabditis elegans mab-9 gene Proteins 0.000 claims description 2
- 101100540120 Caenorhabditis elegans vab-3 gene Proteins 0.000 claims description 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 101100022444 Mus musculus Mab21l1 gene Proteins 0.000 claims description 2
- 101150065403 NECTIN2 gene Proteins 0.000 claims description 2
- 102000002356 Nectin Human genes 0.000 claims description 2
- 108060005251 Nectin Proteins 0.000 claims description 2
- 102100035487 Nectin-3 Human genes 0.000 claims description 2
- 102100035486 Nectin-4 Human genes 0.000 claims description 2
- 108091059809 PVRL4 Proteins 0.000 claims description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 101150091368 mab-20 gene Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108700017028 mouse T cell Ig and ITIM domain Proteins 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 3
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 1
- 238000003491 array Methods 0.000 description 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 3
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235990P | 2015-10-01 | 2015-10-01 | |
| US62/235,990 | 2015-10-01 | ||
| PCT/US2016/054484 WO2017059095A1 (en) | 2015-10-01 | 2016-09-29 | Anti-tigit antigen-binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533371A JP2018533371A (ja) | 2018-11-15 |
| JP2018533371A5 true JP2018533371A5 (enExample) | 2019-11-07 |
| JP7023233B2 JP7023233B2 (ja) | 2022-02-21 |
Family
ID=57113807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536698A Active JP7023233B2 (ja) | 2015-10-01 | 2016-09-29 | 抗ｔｉｇｉｔ抗原結合タンパク質と、その使用方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9713641B2 (enExample) |
| EP (1) | EP3356413B1 (enExample) |
| JP (1) | JP7023233B2 (enExample) |
| KR (1) | KR20180068990A (enExample) |
| CN (1) | CN108368176B (enExample) |
| AR (1) | AR109625A1 (enExample) |
| AU (1) | AU2016331052B2 (enExample) |
| BR (1) | BR112018006531A2 (enExample) |
| CA (1) | CA3000404A1 (enExample) |
| CO (1) | CO2018004743A2 (enExample) |
| DK (1) | DK3356413T3 (enExample) |
| ES (1) | ES2910027T3 (enExample) |
| HU (1) | HUE058755T2 (enExample) |
| IL (1) | IL258394B (enExample) |
| MX (1) | MX391159B (enExample) |
| MY (1) | MY192226A (enExample) |
| PH (1) | PH12018500714A1 (enExample) |
| PL (1) | PL3356413T3 (enExample) |
| PT (1) | PT3356413T (enExample) |
| RU (2) | RU2729379C1 (enExample) |
| SG (1) | SG10201912736UA (enExample) |
| TW (1) | TWI778943B (enExample) |
| UA (1) | UA125062C2 (enExample) |
| WO (1) | WO2017059095A1 (enExample) |
| ZA (2) | ZA201904675B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3259597B1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
| US10227408B2 (en) | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| KR20180068990A (ko) | 2015-10-01 | 2018-06-22 | 포텐자 테라퓨틱스, 인코포레이티드 | 항-tigit 항체-결합 단백질 및 이의 사용 방법 |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| CN112274637A (zh) | 2016-08-17 | 2021-01-29 | 康姆普根有限公司 | 抗tigit抗体、抗pvrig抗体及其组合 |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| CN110621341A (zh) | 2017-04-26 | 2019-12-27 | 百时美施贵宝公司 | 使二硫键还原最小化的抗体生产方法 |
| KR20180120893A (ko) * | 2017-04-28 | 2018-11-07 | 재단법인 목암생명과학연구소 | Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도 |
| US11021537B2 (en) * | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| GB201709808D0 (en) * | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| SG11202000820PA (en) | 2017-07-31 | 2020-02-27 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| WO2019062832A1 (zh) * | 2017-09-29 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | Tigit抗体、其抗原结合片段及医药用途 |
| WO2019070908A1 (en) | 2017-10-03 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS |
| GB2569144B (en) * | 2017-12-06 | 2021-06-16 | Proimmune Ltd | Method for screening the activity of mutated expressed polypeptides |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| AU2018396970B2 (en) * | 2017-12-28 | 2025-09-25 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
| TWI877769B (zh) | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| CN111699200B (zh) | 2018-01-15 | 2023-05-26 | 南京传奇生物科技有限公司 | 针对pd-1的单域抗体和其变体 |
| JP7316284B2 (ja) * | 2018-01-15 | 2023-07-27 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｔｉｇｉｔに対する抗体及びその多様体 |
| KR102511268B1 (ko) * | 2018-02-06 | 2023-03-20 | 아이-맵 바이오파마 (항저우) 컴퍼니 리미티드 | Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용 |
| MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
| KR102825164B1 (ko) | 2018-03-27 | 2025-06-26 | 브리스톨-마이어스 스큅 컴퍼니 | 자외선 신호를 사용한 단백질 농도의 실시간 모니터링 |
| WO2019232484A1 (en) | 2018-06-01 | 2019-12-05 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| AU2019310803B2 (en) | 2018-07-25 | 2022-11-03 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-TIGIT antibody and uses thereof |
| TW202023625A (zh) | 2018-08-23 | 2020-07-01 | 美商西雅圖遺傳學公司 | 抗tigit抗體 |
| JP7484717B2 (ja) | 2018-09-26 | 2024-05-16 | アステラス製薬株式会社 | 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬 |
| JP7467438B2 (ja) | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｒｓｖ抗体の製剤及びその使用方法 |
| CN113015748B (zh) | 2018-10-31 | 2025-12-12 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| KR20210134321A (ko) * | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| CN111744013B (zh) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 |
| US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| AU2020290916A1 (en) * | 2019-06-13 | 2021-11-04 | Green Cross Corporation | Antibody to TIGIT and use thereof |
| CN114729040A (zh) * | 2019-06-21 | 2022-07-08 | 单细胞技术股份有限公司 | 抗tigit抗体 |
| WO2021003074A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
| CN114269782B (zh) * | 2019-07-15 | 2023-12-29 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体及其应用 |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220290179A1 (en) | 2019-08-29 | 2022-09-15 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| JP7628111B2 (ja) * | 2019-09-03 | 2025-02-07 | バイオ － テラ ソリューションズ、リミテッド | 抗ｔｉｇｉｔ免疫阻害剤及び応用 |
| JP7122354B2 (ja) | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗ｔｉｇｉｔ抗体および使用方法 |
| WO2021093849A1 (en) * | 2019-11-14 | 2021-05-20 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel antibody against tigit |
| JP7638989B2 (ja) * | 2019-11-21 | 2025-03-04 | ユニティ バイオテクノロジー インコーポレイテッド | Ｔｉｅ－２に対する抗体および使用方法 |
| WO2021113831A1 (en) | 2019-12-05 | 2021-06-10 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| CN113087806B (zh) * | 2019-12-31 | 2022-09-06 | 华东师范大学 | 靶向多种肿瘤的新型car-t细胞及其制备和方法 |
| CN110818795B (zh) * | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| CN113563470B (zh) | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| TW202216768A (zh) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023138639A1 (zh) * | 2022-01-24 | 2023-07-27 | 原启生物科技(上海)有限责任公司 | 靶向tigit的抗原结合蛋白及其用途 |
| JP2025509274A (ja) | 2022-03-09 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | 治療用タンパク質の一過性発現 |
| PE20251671A1 (es) | 2022-03-15 | 2025-06-30 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer |
| US20250179176A1 (en) | 2022-05-02 | 2025-06-05 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025188136A1 (en) * | 2024-03-04 | 2025-09-12 | Abl Bio, Inc. | Anti-tigit/anti-4-1bb bispecific antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| DE60335552D1 (de) | 2002-09-11 | 2011-02-10 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
| KR101199789B1 (ko) | 2003-03-24 | 2012-11-09 | 더 스크립스 리서치 인스티튜트 | 종양 성장 억제 ｄｎａ 백신 |
| ES2609429T3 (es) | 2005-05-12 | 2017-04-20 | Zymogenetics, Inc. | Composiciones y métodos para modular respuestas inmunitarias |
| EP1907001B1 (en) * | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
| WO2007073478A2 (en) | 2005-12-19 | 2007-06-28 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ， エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| HUE036780T2 (hu) | 2008-04-09 | 2018-07-30 | Genentech Inc | Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére |
| EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
| MX2012013899A (es) | 2010-06-09 | 2013-03-20 | Zymogenetics Inc | Proteinas de fusion vstm3 dimericas y composiciones y metodos relacionados. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| KR102810907B1 (ko) | 2010-07-16 | 2025-05-21 | 아디맵 엘엘씨 | 항체 라이브러리 |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
| EP2834259A4 (en) | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES |
| JP2015520192A (ja) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｈｉｐｐｏ経路を調節する結合剤およびその使用 |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| KR20150090919A (ko) | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
| US20140323315A1 (en) | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| AU2014290069B2 (en) * | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| MY198017A (en) * | 2014-08-19 | 2023-07-26 | Merck Sharp & Dohme | Anti-tigit antibodies |
| KR20170072343A (ko) * | 2014-11-06 | 2017-06-26 | 제넨테크, 인크. | Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법 |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| WO2017037707A1 (en) | 2015-09-02 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
| KR20250021613A (ko) | 2015-09-25 | 2025-02-13 | 제넨테크, 인크. | 항-tigit 항체 및 이의 이용 방법 |
| CN106554347B (zh) | 2015-09-25 | 2020-10-30 | 浙江博生医药有限公司 | Egfr激酶抑制剂及其制备方法和应用 |
| KR20180068990A (ko) | 2015-10-01 | 2018-06-22 | 포텐자 테라퓨틱스, 인코포레이티드 | 항-tigit 항체-결합 단백질 및 이의 사용 방법 |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
-
2016
- 2016-09-29 KR KR1020187011720A patent/KR20180068990A/ko not_active Ceased
- 2016-09-29 MX MX2018003898A patent/MX391159B/es unknown
- 2016-09-29 BR BR112018006531A patent/BR112018006531A2/pt not_active Application Discontinuation
- 2016-09-29 RU RU2018116081A patent/RU2729379C1/ru active
- 2016-09-29 MY MYPI2018701302A patent/MY192226A/en unknown
- 2016-09-29 RU RU2020124191A patent/RU2020124191A/ru unknown
- 2016-09-29 TW TW105131434A patent/TWI778943B/zh not_active IP Right Cessation
- 2016-09-29 DK DK16778648.2T patent/DK3356413T3/da active
- 2016-09-29 CA CA3000404A patent/CA3000404A1/en active Pending
- 2016-09-29 SG SG10201912736UA patent/SG10201912736UA/en unknown
- 2016-09-29 AR ARP160102969A patent/AR109625A1/es not_active Application Discontinuation
- 2016-09-29 UA UAA201803610A patent/UA125062C2/uk unknown
- 2016-09-29 JP JP2018536698A patent/JP7023233B2/ja active Active
- 2016-09-29 WO PCT/US2016/054484 patent/WO2017059095A1/en not_active Ceased
- 2016-09-29 PT PT167786482T patent/PT3356413T/pt unknown
- 2016-09-29 HU HUE16778648A patent/HUE058755T2/hu unknown
- 2016-09-29 CN CN201680070434.6A patent/CN108368176B/zh not_active Expired - Fee Related
- 2016-09-29 PL PL16778648T patent/PL3356413T3/pl unknown
- 2016-09-29 AU AU2016331052A patent/AU2016331052B2/en not_active Ceased
- 2016-09-29 ES ES16778648T patent/ES2910027T3/es active Active
- 2016-09-29 EP EP16778648.2A patent/EP3356413B1/en active Active
-
2017
- 2017-02-13 US US15/430,998 patent/US9713641B2/en active Active
- 2017-06-19 US US15/627,161 patent/US10507244B2/en active Active
-
2018
- 2018-03-27 IL IL258394A patent/IL258394B/en unknown
- 2018-03-28 PH PH12018500714A patent/PH12018500714A1/en unknown
- 2018-05-02 CO CONC2018/0004743A patent/CO2018004743A2/es unknown
-
2019
- 2019-07-16 ZA ZA2019/04675A patent/ZA201904675B/en unknown
- 2019-10-22 US US16/659,797 patent/US11590224B2/en active Active
-
2020
- 2020-07-29 ZA ZA2020/04919A patent/ZA202004919B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533371A5 (enExample) | ||
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| JP7575100B2 (ja) | 免疫細胞活性化のための二重特異性抗体 | |
| JP7009517B2 (ja) | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 | |
| JP2020530289A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| RU2020124191A (ru) | Анти-tigit антиген-связывающие белки и способы их применения | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP2019521645A5 (enExample) | ||
| US12098210B2 (en) | Methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| US12146000B2 (en) | Bispecific and tetravalent CD137 and FAP molecules for the treatment of cancer | |
| KR20210149141A (ko) | 삼중특이적 결합 단백질, 이의 방법 및 용도 | |
| JP2022522662A (ja) | Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用 | |
| JP2019537449A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2025510232A (ja) | Ｉｌｔ３及びｃｄ３結合剤及びその使用方法 | |
| IL323989A (en) | Methods for treating multiple myeloma | |
| JP2021063099A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| US20240279335A1 (en) | Cd28 shedding blocking agents | |
| TW202426503A (zh) | 癌症治療中與ｐｄ－１訊息抑制劑組合之抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體的用途 | |
| JP6881658B2 (ja) | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |